Видео ютуба по тегу Pedro Barata

Uromigos Live 2023: Dr. Pedro Barata on Cisplatin for Bladder Cancer
Uromigos Live 2023: Dr. Pedro Barata on Cisplatin for Bladder Cancer
Dr. Pedro Barata on Sequencing Therapies and Other Treatment Considerations for aRCC
Dr. Pedro Barata on Sequencing Therapies and Other Treatment Considerations for aRCC
Dr. Pedro Barata: Overview of FOTIVDA® (tivozanib)
Dr. Pedro Barata: Overview of FOTIVDA® (tivozanib)
Pedro Barata at Nexans Innovation Summit
Pedro Barata at Nexans Innovation Summit
Dr. Pedro Barata 🇺🇸 Presenting How to Treat Relapse RCC after Adjuvant Treatment #KidneyCancer
Dr. Pedro Barata 🇺🇸 Presenting How to Treat Relapse RCC after Adjuvant Treatment #KidneyCancer
Dr. Pedro Barata on aRCC Diagnosis, Treatment Options, and Progression After ICI Combinations
Dr. Pedro Barata on aRCC Diagnosis, Treatment Options, and Progression After ICI Combinations
Tulane Doctors Health Minutes - Pedro Barata, MD, MSc
Tulane Doctors Health Minutes - Pedro Barata, MD, MSc
Dr. Pedro Barata on Improving Outcomes for Patients With aRCC Who Progress on Initial ICI Treatment
Dr. Pedro Barata on Improving Outcomes for Patients With aRCC Who Progress on Initial ICI Treatment
Pedro Barata
Pedro Barata
ctDNA abnormalities in prostate cancer: distinctions in AA versus Ca patients
ctDNA abnormalities in prostate cancer: distinctions in AA versus Ca patients
10. Abordaje escalonado del cáncer de próstata hormonosensible - Dr. Pedro Barata | Uroconect
10. Abordaje escalonado del cáncer de próstata hormonosensible - Dr. Pedro Barata | Uroconect
Future approaches in CRPC: radioligands, CAR-T and bispecifics
Future approaches in CRPC: radioligands, CAR-T and bispecifics
Pedro Barata: There Is a Different Equity In Making Sure No One Gets Left Behind
Pedro Barata: There Is a Different Equity In Making Sure No One Gets Left Behind
18F-fluciclovine PET in mCRPC treated with abiraterone acetate
18F-fluciclovine PET in mCRPC treated with abiraterone acetate
See the FOTIVDA® (tivozanib) exploratory subgroup analysis from the TIVO-3 trial
See the FOTIVDA® (tivozanib) exploratory subgroup analysis from the TIVO-3 trial
Episode 8: Exploring the Future of Work with Pedro Barata
Episode 8: Exploring the Future of Work with Pedro Barata
Trial updates in prostate cancer from ASCO 2021: VISION, PEACE1, & SWOG S1216
Trial updates in prostate cancer from ASCO 2021: VISION, PEACE1, & SWOG S1216
Exclusive highlights in genitourinary cancer at ASCO 2023
Exclusive highlights in genitourinary cancer at ASCO 2023
Skills Transferability and Future of Work | Pedro Barata
Skills Transferability and Future of Work | Pedro Barata